We studied the elimination of sulfisoxazole in eight renal transplant patients. The patients received sulfisoxazole prophylactically for urinary tract infection commencing 7 days postoperatively. The renal elimination of sulfisoxazole (unbound renal clearance) was decreased in this patient population and was highly correlated with creatinine clearance. The unbound metabolic clearance and apparent unbound formation clearance of N4-acetyl sulfisoxazole did not differ from values found in healthy volunteers. The protein binding was marginally lower in this patient population than in healthy subjects after a single dose. The reduced binding was compatible with a reduced albumin concentration. In contrast to the situation for healthy subjects, the binding of sulfisoxazole decreased upon multiple dosing. This is probably due to a relatively higher sulfisoxazole and N4-acetyl sulfisoxazole-to-albumin ratio in this patient population than in healthy subjects. No complications of sulfisoxazole therapy were seen, although in three subjects concentration of the N4-acetyl sulfisoxazole in urine exceeded its theoretical solubility on a few occasions.
Sulfisoxazole is often used as a prophylactic antibacterial agent in renal transplant patients to reduce the likelihood of urinary tract infections during the postoperative recovery phase (2) . Sulfisoxazole has been safely used in this patient population in a number of institutions including our own (3, 6) .
Several concerns exist regarding the use of sulfisoxazole in the transplant population. Renal function is generally lower than normal, which causes an increased risk of crystalluria. However, the risk is usually considered to be low (1) , mainly owing to the high solubility of both sulfisoxazole and its primary metabolite N4-acetyl sulfisoxazole (13). Because of the reduced renal function, the fraction excreted unchanged in the urine is decreased and may compromise the effectiveness of therapy. Reidenberg et al. (11) have also suggested that the metabolism of sulfisoxazole may be decreased in subjects with decreased renal function. The mechanism for such a decrease is unclear, but data obtained with experimental animals have suggested that sulfisoxazole may be renally metabolized (4) and that decreased renal function may subsequently result in a decreased metabolic clearance. In addition, data obtained with experimental animals have suggested that N4-acetyl sulfisoxazole may inhibit its own formation (8, 9) . Moreover, there is a reported decrease in the protein binding of sulfisoxazole in renal failure (14), which significantly affects both the clearance and distribution.
This study was undertaken to evaluate the disposition and urinary excretion of sulfisoxazole and N4-acetyl sulfisoxazole in postrenal transplant patients being treated prophylactically with sulfisoxazole.
MATERIALS AND METHODS Protocol. (i) Subjects. Six male and two female patients receiving cadaver kidney transplants were studied. The patients received 500 to 1,000 mg of sulfisoxazole (Gantrisin) orally two (b.i.d.) to four (q.i.d.) times per day, as prescribed by their primary care physician. Dose size was generally based on 24-h creatinine clearance values. Treatment commenced approximately 7 days after the transplant, at which time the urinary catheter inserted during the surgery was removed. All patients studied had hematocrit values of > 20%, few had abnormal liver function tests, none had histories of allergy to sulfisoxazole, and none were given other antibiotics during the treatment period. Laboratory data for the eight patients are presented in Table 1 .
Four or five 4-ml blood samples were obtained during the first dosing interval after initiation of drug therapy and again during a dosing interval on days 4 and 7 after the start of therapy. At the 6-h dosing interval samples were obtained at 0, 2, 4, and 6 h, and at the 12-h dosing interval blood samples were obtained at 0, 2, 4, 8, and 12 h. The samples were obtained by venipuncture and allowed to clot, and the serum was separated by centrifugation at 700 x g for 20 min. The serum was collected and kept frozen (-20°C) until assayed. Urine was collected every 2 h during the blood sampling periods; otherwise, the total daily urine was collected at 24-h intervals for the remainder of the hospital stay of each patient or until sulfisoxazole administration was discontinued. The urine volume and pH were determined for each urine sample, and a sample was stored frozen (-20°C) until assayed.
(ii) Normal volunteers. Six healthy male volunteers ranging in age from 23 to 34 years were studied. Sulfisoxazole disposition was determined after a 1,000-mg single oral dose, during a 1,000-mg intravenous bolus dose, and during a multiple dosing regimen of 500 mg q.i.d. The results for the normal volunteers have been presented in detail previously (10) .
Protein binding. A 1-ml portion of serum was placed in a Millipore 10-mm dialysis cell (xx 42 01310) equipped with a magnetic stirrer. Serum water was filtered through a 25,000-MW cutoff filter (Millipore PSED) with nitrogen (pressure, 3.5 bar [3.5 x 105 Pa]) containing 1.4% CO (50 mbar [5 x 103 Pa]). The ultrafiltration was carried out at 370C.
Two aliquots of 100 RI of serum filtrate each were collected and assayed for sulfisoxazole. The concentration of sulfisoxazole in the second 100-,u aliquot never exceeded the first by more than 10%, and this aliquot was used for the reported serum water concentration of sulfisoxazole. Repeated determinations of the unbound fraction of sulfisoxazole in the samples yielded a coefficient of variation 0.042 (n = 22) in the normal subjects and 0.051 (n = 8) in the renal transplant patients. Assay methods. Sulfisoxazole and its major metabolite, N4-acetyl sulfisoxazole, in serum and urine were determined by a specific high-pressure liquid chromatographic method, described previously (7). Total sulfisoxazole (unchanged drug and metabolites) in urine was determined by hydrolysis of the urine samples with hydrochloric acid at 100°C as described by Rieder (12) together with the colorimetric assay method described by Bratton and Marshall (5) as modified by 0ie (9) . Urine obtained from the individual patients before sulfixazol administration was used a blank. The coefficient of variation at 20 mg/ml was 2.3% (n = 9) with this procedure.
Treatment of data. Treatment of the results from the healthy volunteers was described previously (10) . The renal clearance values in the renal transplant patients were obtained by determining the total amount of drug collected in urine during the dosing interval divided by the area under the serum concentration-time curve for the same interval. The area was obtained by using the trapezoidal rule. The unbound clearance-bioavailability was obtained by dividing the administered dose per dosing interval by the area under the unbound serum concentration-time curve during the same interval. For the latter calculation we assumed that steadystate conditions had been reached.
The formation clearance of N4-acetyl sulfisoxazole was determined by dividing the molar amount of N4-acetyl sulfisoxazole in urine by the area under the serum concentration-time curve of sulfisoxazole, expressed in molar concentrations. For this calculation we assumed that N4-acetyl sulfisoxazole was essentially eliminated in the urine as unchanged N4-acetyl sulfisoxazole and was metabolized further only to an insignificant degree.
The unbound fraction value reported is the ratio of the area under the concentration-time curve in serum water (serum filtrate) to the area under the concentration-time curve in serum, and represents the time-averaged observed value.
RESULTS
A typical serum concentration-time plot of a representative patient is shown in Fig. 1 . Average recovery from urine with time of sulfisoxazole, sulfisoxazole plus N4-acetyl sulfisoxazole, and total sulfisoxazole, is given in Fig. 2 .
Average concentrations of urine, their ranges and standard deviations, urine flow rate, and pH for the individual subjects are presented in Table 2 . The unbound clearancebioavailability, of sulfisoxazole is given in Table 3 , together with the unbound fraction values of sulfisoxazole over the three study days. The bioavailability of sulfisoxazole based on unbound drug in the normal control subjects was 0.95 + .z_o *-.* _,-_usually corresponded to study day 4. In two subjects, *\, v creatinine clearance was determined in conjunction with two J * of the study periods; both are reported. The unbound fraction of sulfisoxazole was higher in the renal transplant patients than in the control subjects, both on day 1 and on the last study day (t = 2.489, P < 0.05, and t = _|* U 4.215, P < 0.001, respectively). The difference on day 1 *.-mNu/wf \ / appears to correspond to the difference in albumin concentration between these groups (3. groups was found (t = 3.362, P < 0.01). TIME, DAYS
The excretion of sulfisoxazole from urine, on average, appeared to increase with time. The increase seemed to Average recovery from urine with time of sulfisoxazole correspond to an improvement in the renal function, as nbined sulfisoxazole and N4-acetyl sulfisoxazole (A), evidenced by the decreasing creatinine concentration in sulfisoxazole determined by the Bratton-Marshall (5) serum with time. An exception appeared to occur between <i). Average creatinine values in serum, calculated as days 6 and 10, when patient no. 6 experienced a rejection 'CR,), are plotted for comparison (-).
period, resulting in a significantly increased creatinine level in serum.
The excretion of sulfisoxazole from urine correlated with ). With the assumption that the bioavailability is the creatinine concentration in serum in only two of the In renal transplant patients, the values in Table 3 transplant patients (no. 2 and 6; P < 0.025 by the Student t ated as the clearance values. test).
The total unbound clearance (CLu), as well as the unbound renal clearance (CLuR), were statistically significantly lower in the transplant patients than in the control subjects (t = 2.286, P < 0.05, and t = 3.199, P < 0.01, respectively).
The unbound extrarenal clearance (CLuxR) and the unbound formation clearance of N4-acetyl sulfisoxazole in the transplant patients were, on the other hand, not statistically significantly different from the control values (t = 0.265, P > 0.70, and t = 1.324, P > 0.20, respectively). The lower CLu therefore seems to be a result of the decreased renal elimination of sulfisoxazole. The CLUR of sulfisoxazole in the study subjects correlated highly with the measured creati-
DISCUSSION
The elimination of sulfisoxazole (CLu) in renal transplant patients is similar to that found in normal subjects when differences in renal function are taken into consideration. There is no evidence of reduced metabolic elimination similar to that suggested by Reidenberg et al. (11) in renal failure subjects or to what was found in renal failure animals (9a). This is probably a consequence of only a moderately reduced renal function in our patients compared with those in the other studies. -neral, the unbound fraction of sulfisoxazole increased dependent binding of sulfisoxazole. At steady state, the tinued administration of sulfisoxazole. The unbound average molar concentration of sulfisoxazole (324 ,uM) and n was statistically significantly lower during the first N4-acetyl sulfisoxazole (254 ,uM) approached the average interval than in the later test periods (P < 0.02 by the molar concentration of albumin (560 ,uM) in these patients. it t test). This suggests a time-or concentration-
In the normal subjects, the average molar albumin concentration was 650 ,uM, and saturable protein binding of sulfisoxazole after intravenous dosing was seen only at concentrations of sulfisoxazole in excess of 300 ,uM (8).
Since N4-acetyl sulfisoxazole and sulfisoxazole compete for the same binding site(s) and the combined molar concentrations of these compounds are equal to the molar concentration of albumin in the renal transplant patients, the / decreased binding is probably due to a concentrationo°/ dependent effect. In all patients the unbound concentrations in plasma, as well as those in urine, were at all times after the first dose at levels considered to be active against sulfisoxazole-susceptible microorganisms.
The total recovery of sulfisoxazole and N4-acetyl sulfisoxazole over the total study period was 63.5 ± 7.4%, compared with a recovery in normal controls of 80% (9) . With the use of the Bratton-Marshall method for total sulfisoxazole (5), 92% of the dose could be accounted for after hydrolysis, which is lower than that observed in healthy controls (109%). Part of the lower total recovery is probably related to the difficulty in assuring complete urine collection over the 12-to 21-day study period for the individual patients. During the steady state, when three or more 2-h urine samples were collected, the recovery by the Bratton-Marshall method was 99%. Similarly, the sulfisoxazole and N4-acetyl sulfisoxazole recovery was 36 and 38%, respectively, versus 32% each for the total study period. It therefore appears to be unlikely that total recovery of sulfisoxazole from urine was achieved consistently throughout the study. The total recovery of sulfisoxazole was, on the other hand, only correlated with the daily urine flow in one of the eight patients (P < 0.05 by the Student t test). A correlation was only expected if a large amount of urine was lost on occasions; this indicates that the urine volume lost due to inadequate collection is small. The clearance determination samples were, on the other hand, collected under more controlled conditions and are likely to better represent the ability to eliminate sulfisoxazole.
The excretion of sulfisoxazole from urine did not consistently vary with urine pH, urine flow rate, or creatinine levels in serum in individual subjects. Several reasons may account for this phenomenon. The urine pH, urine flow rate, and creatinine levels in serum tended to vary relatively little throughout the study in the individual patients. Only when large changes were seen in urine pH, urine flow rate, and creatinine levels in serum could a correlation be found.
In all subjects (transplant patients and controls), the majority of the variability in the CLUR of sulfisoxazole could be explained by the difference in creatinine clearance values (Fig. 3) . It is, however, interesting to note that the linear relationship between CLUR and creatinine clearance has a negative intercept on the y axis. Because the four subjects with the lowest CLus were among the subjects with the lowest urine pH, the deviation from a straight line through the origin may be due to higher-than-average reabsorption in these subjects. However, the r2 value for the multiple correlation between CLUR and creatinine clearance, urine flow rate, and urine pH (0.8823) was not marginally different from the r2 value for the correlation between CLUR and creatinine clearance alone (0.8597).
In summary, the kinetics of unbound sulfisoxazole in renal transplant patients was predictable from data in normal volunteers after adjusting for differences in renal function. Differences in the kinetics of total sulfisoxazole were, on the other hand, quite notable, mainly owing to a lower binding to protein in plasma in the renal transplant patients. The lowered binding could be related to a lower albumin concentration and an accumulation of N4-acetyl sulfisoxazole, a displacer of sulfisoxazole.
